Company Overview
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Why Investors Should Care
Revenue has grown at a 19.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.23.
Recent Developments
- Dec 2025 Revenue of $200.93M (+20.2% YoY); net profit $-18.90M.
- Trailing 12 Months Year-on-year growth — revenue +15.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.60% |
| 1 Year: | 15.20% |
Stock Price Performance
| 1 Year: | +17.83% |
| 6 Months: | +33.77% |
| 3 Months: | +22.35% |
| 1 Month: | +1.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)46.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SIBN SI-BONE, Inc. R2KR3KPHARMA | 18.50 | -54.41 | $820.46M | 0.00% | -10.47% | -8.30% | 19.60% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 14.99M | 16.32M | 16.18M | 16.82M | 14.05M | 20.37M | 20.44M | 22.19M | 22.29M | 22.44M | 25.59M | 26.43M | 32.71M | 33.30M | 34.01M | 37.87M | 39.97M | 40.34M | 47.29M | 48.63M | 48.66M | 52.59M | 56.01M |
| Gross Profit | 10.36M | 11.66M | 12.48M | 12.16M | 13.46M | 14.73M | 14.55M | 14.89M | 11.93M | 17.80M | 18.24M | 19.82M | 19.81M | 19.46M | 22.12M | 22.26M | 26.78M | 26.99M | 26.97M | 29.86M | 31.58M | 31.90M | 37.70M | 38.81M | 38.85M | 41.94M | 44.55M |
| Operating Income | -5.04M | -2.92M | -1.70M | -3.04M | -8.80M | -8.14M | -10.58M | -11.88M | -10.14M | -8.68M | -11.57M | -12.96M | -13.20M | -16.87M | -17.88M | -13.57M | -11.29M | -11.96M | -11.17M | -12.04M | -10.08M | -7.63M | -7.48M | -7.00M | -5.38M | -5.09M | -4.81M |
| Net Income | -5.68M | -4.20M | -3.15M | -4.79M | -9.35M | -8.65M | -11.31M | -12.77M | -12.47M | -9.47M | -12.24M | -13.98M | -15.87M | -17.41M | -18.51M | -14.16M | -11.12M | -11.21M | -10.02M | -10.90M | -8.94M | -6.58M | -6.54M | -6.15M | -4.57M | -4.33M | -4.09M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.44 | -0.33 | -0.37 | -0.42 | -0.48 | -0.52 | -0.54 | -0.41 | -0.32 | -0.30 | -0.25 | -0.27 | -0.22 | -0.16 | -0.15 | -0.14 | -0.11 | -0.10 | -0.09 |
| R&D Expense | 1.47M | 1.21M | 1.30M | 1.37M | 1.68M | 1.95M | 1.87M | 2.09M | 2.17M | 2.78M | 2.96M | 3.15M | 3.29M | 3.58M | 3.48M | 3.09M | 3.29M | 3.66M | 3.92M | 4.34M | 4.35M | 3.99M | 4.53M | 4.31M | 4.24M | 4.19M | 5.22M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 47.98M | 55.38M | 67.30M | 73.39M | 90.15M | 106.41M | 138.89M | 167.18M | 200.93M |
| Gross Profit | 42.87M | 50.55M | 60.51M | 64.48M | 79.72M | 90.70M | 109.42M | 132.12M | 159.88M |
| Operating Income | -17.35M | -11.96M | -36.00M | -38.57M | -51.67M | -59.61M | -46.93M | -35.25M | -22.33M |
| Net Income | -23.04M | -17.45M | -38.40M | -43.70M | -56.57M | -61.26M | -43.34M | -30.91M | -18.90M |
| Diluted EPS | - | - | - | -1.50 | -1.71 | -1.79 | -1.13 | -0.75 | -0.44 |
| R&D Expense | 5.51M | 5.38M | 7.28M | 9.46M | 12.44M | 13.63M | 15.03M | 16.56M | 17.45M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 35.83M | 138.52M | 117.01M | 223.14M | 190.51M | 157.55M | 230.43M | 230.44M | 238.56M |
| Total Equity | -108.73M | -129.38M | 90.19M | 63.01M | 169.36M | 134.42M | 98.30M | 169.38M | 166.96M | 177.53M |
| Cash & Equivalents | 27.90M | 22.41M | 25.12M | 10.44M | 53.58M | 63.42M | 20.72M | 33.27M | 34.95M | 42.24M |
| Long Term Debt | - | 38.70M | 38.96M | 34.87M | 39.45M | 34.97M | 35.17M | 36.06M | 35.45M | 35.57M |
| Total Liabilities | - | 46.66M | 48.33M | 54.00M | 53.78M | 56.09M | 59.25M | 61.05M | 63.47M | 61.02M |
| Current Liabilities | - | 7.54M | 9.01M | 18.77M | 13.47M | 16.89M | 21.18M | 23.46M | 27.13M | 25.28M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.53M | -14.52M | -31.63M | -30.66M | - | -41.66M | -18.71M | -12.43M | -675.00K |
| Investing Cash Flow | -478.00K | -97.83M | 13.49M | -62.92M | - | -2.81M | -59.80M | 12.62M | 4.16M |
| Financing Cash Flow | 12.86M | 115.15M | 3.49M | 136.40M | - | 2.20M | 90.93M | 1.96M | 3.38M |
| Capital Expenditure | -478.00K | -942.00K | -2.44M | -2.56M | - | -9.51M | -7.80M | -10.50M | -8.41M |
| Free Cash Flow | -18.01M | -15.46M | -34.07M | -33.22M | - | -51.16M | -26.51M | -22.92M | -9.09M |
| Net Change in Cash | - | - | - | - | - | -42.27M | 12.42M | 2.16M | 6.86M |
| Share Buybacks | 0 | 73.00K | 38.00K | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 89.3% | 91.3% | 89.9% | 87.9% | 88.4% | 85.2% | 78.8% | 79.0% | 79.6% |
| Operating Margin % | -36.2% | -21.6% | -53.5% | -52.6% | -57.3% | -56.0% | -33.8% | -21.1% | -11.1% |
| Net Margin % | -48.0% | -31.5% | -57.1% | -59.5% | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
| ROE % | 17.8% | -19.4% | -60.9% | -25.8% | -42.1% | -62.3% | -25.6% | -18.5% | -10.6% |
| ROCE % | -61.3% | -9.2% | -36.6% | -18.4% | -29.8% | -43.7% | -22.7% | -17.3% | -10.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 18.33% | 8.13M | $156.14M |
| 2 | Blackrock Inc. | 8.29% | 3.68M | $70.62M |
| 3 | Cadian Capital Management, LP | 7.55% | 3.35M | $64.31M |
| 4 | American Century Companies Inc | 5.66% | 2.51M | $48.24M |
| 5 | Brown Advisory Inc. | 4.68% | 2.08M | $39.90M |
| 6 | Granahan Investment Management LLC | 4.35% | 1.93M | $37.10M |
| 7 | Vanguard Capital Management LLC | 4.15% | 1.84M | $35.32M |
| 8 | Impax Asset Management Group plc | 3.21% | 1.43M | $27.37M |
| 9 | Gilder Gagnon Howe & Co LLC | 2.83% | 1.25M | $24.07M |
| 10 | Paradigm Capital Management | 2.78% | 1.23M | $23.69M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SIBN
SI-BONE (SIBN) director exercises options, sells 20K shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNS1sWGhGR2dqcHBUYmt4bUVzbXdvenhOLXI5bk5EMXZNVURTNjE1anNHSTlRN21mNmpMVFFrM08ydDhyQ1NOMHJEb3ZuSVhGWURTYTZ3ZTB2UGdpSmdOcDFGcHk0ZV9VaTZzZlVMZDJkamJMX3d0LWxKUlo2N0swSG53RFFCeXNPRFhsYT…
Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNY2ZNZENseGpxZVVnSk9TU2lYNzJna05zOFdqbFFwQUlTUk9GS0dLZVdKSFY5QktxRUppMXBhck5QRmtGbFdVUjBQdmZUZ0d4QlVJWlpVZlF0dlVsRXlOSWFIV1NkY1MyUkl1QzlqRkhFOGVVNUUzaDJxUk1TdGZGdDE5OW1ITnJxbU5mcl…
SIBN stock focus on SI-BONE market and fundamentals - ad-hoc-news.de
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQSzNNVlBCaFllMDZtNVlsRW5vSmJXakVQMG5VX2tTaWY2ZTlHeU5Pc0JqOElQelpBZVYyN2t4ZTBhZmx2WDZ2cXVmc0EwdE9LbFBiSElxd1dMTjJtc2pEUzg5TVh1RzF4emFLNHYxZ3lEeGt1LWNXb3pOUktYREdKci1XUmF5cWo4Mjh0QW…
Si-Bone director Jeffrey Dunn sells $378,160 of common stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNWFEyU21INDdPcEJoaENwSVR0cnlBVy1mVXVNeERFNW1EX05vcy1SMV9QcE5fUHJNVFM2ZGdKTFhnZ1JLUHRJQ2RpVXp3RTBZX1A4VGFyZ09hZXlfODk3aXRDUjYzSlNWQWtvSFRfQmhNazhTV19neTlLbFNfSlRSOEZHNHFQYkJ5SVpPbG…
This Insider Has Just Sold Shares In SI-BONE - simplywall.st
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQamlvWW9Pb0Q2aDUxY3ZCOS0zM0Exa0dvcHZScHlCNThZa2sxX183bks2QllPOGpsWFljTTMwUWRPRXNaMHFjNXR0bklaYmpMQXpDdlRHLUxlcUE4dXRDSlQ0TGNRMmJ1NTM0ZGtOc1laZ2xnd2NHSElIakdwX2VnZVgwNGcycmUySVRLU3…
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQQWpmR0wwVlcyTUk5RVFid2Jrc2VURTNPZUtMS3lrbTlMdW80cG9ROHdqdXZyaHNYSHQ2dl9WUDFWUHRtWV9Vd0t5RVpVaVFycDJjT2w4TFZwUEpkeEFaZFd1S1ZRcEZfZEg4dlVVN29BYjU5ZFJfMVIxTEtNUEVKN2J4Q19NZTViY0RKaX…
SIBN — Frequently Asked Questions
What is the current share price of SI-BONE, Inc. (SIBN)?
As of 2026-09-07 16:24 PDT, SI-BONE, Inc. (SIBN) trades at $18.50 on NasdaqGM. Its 52-week range is $11.61 to $21.40.
What is the market capitalisation of SIBN?
SI-BONE, Inc. (SIBN) has a market capitalisation of $820.46M on NasdaqGM.
What is the P/E ratio of SIBN?
SIBN trades at a trailing price-to-earnings (P/E) ratio of -54.41. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.60.
What is the return on equity (ROE) of SIBN?
SIBN has a return on equity (ROE) of -8.30%. Its return on capital employed (ROCE) is -10.47%.
Is SIBN a good stock to buy?
This page provides a data-driven analysis of SI-BONE, Inc. (SIBN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.